Skip to main content
SpringerLink
Log in

Could aminoglutethimide replace adrenalectomy?

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Could aminoglutethimide replace adrenalectomy? This question has already been answered in clinical practice in the United Kingdom, for surgical adrenalectomy has declined markedly in frequency as new hormonal therapy has appeared. An optimal assessment of an endocrine therapy can only be made in previously untreated patients because of the heterogeneity of previously treated populations. Thus aminoglutethimide (AG) and adrenalectomy have been compared for previously untreated and treated populations. Because AG is commonly called ‘medical adrenalectomy’, this article will review and compare aminoglutethimide therapy with surgical adrenalectomy and make the case that surgical adrenalectomy is no longer indicated in the management of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hughes SWM, Burley DM: Aminoglutethimide. A ‘sideeffect’ turned to therapeutic advantage. Postgrad Med J 46:409, 1970

    PubMed  Google Scholar 

  2. Rallison ML, Kumagai LF, Tyler FH: Goitrous hypothyroidism induced by aminoglutethimide, anticonvulsant drug. J Clin Endocrinol Metab 27:265, 1967

    PubMed  Google Scholar 

  3. Pittmann JA, Brown RW: Antithyroid and antiadrenocorticoid activity of aminoglutethimide. J Clin Endocrinol Metab 26:1014, 1966

    PubMed  Google Scholar 

  4. Cash R, Petrini MA, Brough AJ: Ovarian dysfunction associated with an anticonvulsant drug. JAMA 208:1149, 1969

    PubMed  Google Scholar 

  5. Cash R, Brough AJ, Cohen MNP, Satoh PS: Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis. Mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27:1239, 1967

    PubMed  Google Scholar 

  6. Santen RJ, Lipton A, Kendall J: Successful medical adrenalectomy with aminoglutethimide. Role of altered drug metabolism. JAMA 230:1661, 1974

    PubMed  Google Scholar 

  7. Harris AL, Dowsett M, Smith IE, Jeffcoate SL: Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Brit J Cancer 47:621, 1983

    PubMed  Google Scholar 

  8. Touitou Y, Bogdan A, Legrand JC, Desgrez P: Aminoglutethimide and glutethimide: Effects on 18-hydroxycorticosterone biosynthesis by human and sheep adrenals in vitro. Acta Endocrinol 80:517, 1975

    PubMed  Google Scholar 

  9. Fishman LM, Liddle GW, Island DF, FLeischer N, Kuchel O: Effects of aminoglutethimide on adrenal function in man. J Clin Endocrinol Metab 27:481, 1967

    PubMed  Google Scholar 

  10. Santen RJ, Wells SA Jr: The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast. Cancer 46:1066, 1980

    PubMed  Google Scholar 

  11. Kowal J: Adrenal cells in tissue culture. IV. Use of an inhibitor of steroid synthesis for the study of ACTH action. Endocrinol 85:270, 1969

    Google Scholar 

  12. Dexter RN, Fishmann LM, Ney RL, Liddle GW: Inhibition of adrenal corticosteroid synthesis by aminoglutethimide. Studies of the mechanism of action. J Clin Endocrinol Metab 27:473, 1967

    PubMed  Google Scholar 

  13. Gower DB: Modifiers of steroid-hormone metabolism. A review of their chemistry, biochemistry and clinical applications. J Steroid Biochem 5:501, 1974

    PubMed  Google Scholar 

  14. Samojlik E, Santen RJ: Adrenal suppression with aminoglutethimide. III. Comparison of plasma Δ4 and Δ5-steroids in postmenopausal women treated for breast carcinoma. J Clin Endocrinol Metab 47:717, 1978

    PubMed  Google Scholar 

  15. Harris AL, Dowsett M, Smith IE, Jeffcoate S: Hydrocortisone alone versus hydrocortisone plus aminoglutethimide: A comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer 20:463, 1984

    Google Scholar 

  16. Bird CE, Masters VE, Sterns EE, Clark AF: Effects of aminoglutethimide on Δ5-androstenediol metabolism in postmenopausal women with breast cancer. Cancer Res 42:4797, 1982

    PubMed  Google Scholar 

  17. Vermeulen A, Paridaens R, Heuson JC: Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol 19:673, 1983

    Google Scholar 

  18. Badder EM, Lerman S, Santen R: Aminoglutethimide stimulates extra adrenal Δ4-androstenedione production. J Surg Res 34:380, 1983

    PubMed  Google Scholar 

  19. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207, 1973

    PubMed  Google Scholar 

  20. Poortman J, Thijssen JHH, Schwarz F: Androgen production and conversion to estrogens in normal postmenopausal women and in selected breast cancer patients. J Clin Endocrinol Metab 37:101, 1973

    PubMed  Google Scholar 

  21. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E: Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47:1257, 1978

    PubMed  Google Scholar 

  22. Graves PE, Salhanick HA: Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinol 105:52, 1979

    Google Scholar 

  23. Miller WR, Hawkins RA, Forrest APM: Significance of aromatase activity in human breast cancer. Cancer Res 42 (Suppl) 3365S, 1982

  24. Perel E, Blackstein ME, Killinger DW: Aromatase in human breast carcinoma. Cancer Res 42 (Suppl):3369S, 1982

  25. Abul-Hajj, YJ: Comparative studies of aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumours. Cancer Res 42 (Suppl):3373S, 1982

    Google Scholar 

  26. Santen RJ, Santner SJ, Tilsen-Mallett N, Rosen HR, Samojlik E, Veldhuis JD:In vivo andin vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Res 42 (Suppl):3357S, 1982

    Google Scholar 

  27. Samojlik E, Santen RJ, Worgul TJ: Plasma estrone-sulphate. Assessment of reduced estrogen production during treatment of metastatic breast cancer. Steroids 39:497, 1982

    PubMed  Google Scholar 

  28. Santen RJ, Wells SA, Cohn N, Demers LM, Misbin RI, Folts EL: Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide. J Clin Endocrinol Metab 45:739, 1977

    PubMed  Google Scholar 

  29. Maclouf J, Sors H, Rigaud M: Recent aspects of prostaglandin biosynthesis: A review. Biomed 26:362, 1977

    Google Scholar 

  30. Harris AL, Mitchell MD, Smith IE, Powles TJ: Suppression of plasma 6-ketoprostaglandin F1α and 13, 14-dihydro-15-ketoprostaglandin F2α by aminoglutethimide in advanced breast cancer. Brit J Cancer 48:595, 1983

    PubMed  Google Scholar 

  31. Santen RJ, Samojlik E, Wells SA: Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 51:473, 1980

    PubMed  Google Scholar 

  32. Harris AL, Dowsett M, Jeffcoate SL, McKinna JA, Morgan M, Smith IE: Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 55:718, 1982

    PubMed  Google Scholar 

  33. Nicholls PJ, Dalrymple PD, Eweiss N, Douglas JS: Aminoglutethimide metabolism and pharmacokinetics. 13th Intl Congr Chemother (Aug 28-Sept 2, Vienna) SY96, 1983

  34. Thompson TA, Vermeulen JD, Wagner WE, Lesher AR: Aminoglutethimide bioavailability, pharmacokinetics and binding to blood constituents. J Pharm Sci 70:1040, 1981

    PubMed  Google Scholar 

  35. Murray FT, Santner S, Samojlik EA, Santen RJ: Serum aminoglutethimide levels: Studies of serum half-life, clearance and patient compliance. J Clin Pharmacol 19:704, 1979

    PubMed  Google Scholar 

  36. Mauri M, Nunziata C, Gamucci T, Natali M, Calabresi F: GGT elevation associated with aminoglutethimide therapy in advanced breast cancer. 2nd Eur Conf Clin Oncol Abst 17, 1983

  37. Schteingart DE, Conn JW: Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome. J Clin Endocrinol Metab 27:1657, 1967

    PubMed  Google Scholar 

  38. Jarman M, Foster AB, Goss PE, Griggs LJ, Howe I, Coombes RC: Metabolism of aminoglutethimide in humans: Identification of N-hydroxylaminoglutethimide as an autoinduced metabolite. Biomed Mass Spectrum (In press)

  39. Coombes RC, Foster AB, Harland SJ, Jarman M, Nicer EC: Polymorphically acetylated aminoglutethimide in humans. Brit J Cancer 46:340, 1982

    PubMed  Google Scholar 

  40. Brunning PF, Bonfrer JGM: Aminoglutethimide and oral anticoagulant therapy. Lancet ii:582, 1983

    Google Scholar 

  41. Uzgiris VI, Whipple CA, Salhanick HA: Stereoselective inhibition of cholesterol side chain cleavage by enantiomers of aminoglutethimide. Endocrinol 101:89, 1977

    Google Scholar 

  42. Worgul TJ, Santen RJ, Samojlik E, Wells SA: How effective is surgical adrenalectomy on lowering steroid hormone concentrations? J Clin Endocrinol Metab 54:22, 1982

    PubMed  Google Scholar 

  43. Bolufer P, Antonio P, Garcia R, Munoz J, Rodriguez A, Romeu A: Role of the ovary in the regulation of sex hormone binding globulin and its contribution to peripheral levels of androstenedione. Exp Clin Endocrinol 82:29, 1983

    PubMed  Google Scholar 

  44. Paicoff GR, Harmon R, Van Prohasaka J: Effect of adrenalectomy on mammary carcinoma. Arch Surg 85:800, 1962

    PubMed  Google Scholar 

  45. Atkins H, Bulbrook RD, Falconer MA, Hayward JL, MacLean KC, Schurr PH: Urinary steroids in the prediction of response to adrenalectomy or hypophysectomy. Lancet ii:1261, 1968

    Google Scholar 

  46. Fraccia AA, Farrow JH, Miller TR, Tollefsen RH, Greenberg EJ, Knapper WH: Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast. Surg Gynaecol Obstet 133:241, 1971

    Google Scholar 

  47. Byron R, Yonemoto RH, Bashore R, Bierman HR, Cronemiller P, Masters H: Bilateral adrenalectomy in advanced breast carcinoma. Surgery 52:725, 1962

    PubMed  Google Scholar 

  48. Bennett RC: Long-term follow-up of surgical adrenalectomy for breast cancer. Aust NZ J Surg 53:415, 1983

    Google Scholar 

  49. Yonemoto RH, Tan MSC, Byron RL, Riihimaki DU, Keating J, Jacobs W: Randomised sequential hormonal therapy vs. adrenalectomy for metastatic breast carcinoma. Cancer 39:547, 1977

    PubMed  Google Scholar 

  50. Cade S: Adrenalectomy for disseminated breast cancer. Brit Med J ii:613, 1966

    Google Scholar 

  51. Dao TLY, Huggins C: Bilateral adrenalectomy in the treatment of cancer of the breast. Arch Surg 71:645, 1955

    Google Scholar 

  52. Hellstrom J, Franksson C: Adrenalectomy in cancer of the breast. In: Currie AR, Illingworth CFW (eds): Endocrine Aspects of Breast Cancer. Livingstone, 1958, p. 5

  53. Harris AL, Powles TJ, Smith IE, Coombes RC, Ford HT, Gazet JC, Harmer CL, Morgan M, White H, Parsons CA, McKinna JA: Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 19:11, 1983

    PubMed  Google Scholar 

  54. Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, White H, Parsons CA, Villards A, Walsh G, McKinna JA: Tamoxifen versus aminoglutethimide in the treatment of advanced breast carcinoma: A control randomised cross-over trial. Brit Med J 283:1432, 1981

    Google Scholar 

  55. Gale KE: Treatment of advanced breast cancer with aminoglutethimide. A 14 year experience. Cancer Res 42 (Suppl):3389S, 1982

  56. Murray RML, Pitt P: Aminoglutethimide in tamoxifenresistant patients: the Melbourne experience. Cancer Res 42 (Suppl):3437S, 1982

  57. Santen RJ, Worgul TJ, Harvey H, Lipton A, Boucher A, Samojlik E, Wells S: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma: Correlation of clinical and hormonal responses. Ann Intern Med 96:94, 1982

    PubMed  Google Scholar 

  58. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G, Shafik A: A randomised trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50:2265, 1982

    PubMed  Google Scholar 

  59. Troner MB: Aminoglutethimide in the treatment of metastatic breast cancer. Cancer Res 42 (Suppl):3402S, 1982

  60. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA: A randomised trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545, 1981

    PubMed  Google Scholar 

  61. McDonald I. Endocrine ablation in disseminated mammary carcinoma. Surg Gynecol Obstet 115:215, 1962

    PubMed  Google Scholar 

  62. Nemoto T, Patel J, Rosner D, Dao TL: Tamoxifen versus adrenalectomy in metastatic breast cancer. Cancer 53:1333, 1984

    PubMed  Google Scholar 

  63. Dao TL, Nemoto T: Steroid receptors and response to endocrine ablations in women with metastatic cancer of the breast. Cancer 46:2779, 1980

    PubMed  Google Scholar 

  64. Byar DP, Sears ME, McGuire WL: Relationship between oestrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer 15:299, 1979

    PubMed  Google Scholar 

  65. Lawrence DV, Lipton A, Harvey HA, Santen RJ, Wells SA Jr, Cox CE, White DS: Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide. Cancer 45:786, 1980

    PubMed  Google Scholar 

  66. Paridaens R, Leclerq G, Heuson JC: Estrogen receptor status and the clinical response to a combination of aminoglutethimide and cortisol in advanced breast cancer. Rec Results Cancer Res 91:248, 1984

    Google Scholar 

  67. Gale KE, Gelman R, Tormey D, Cummings F: Hormone therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 2:C409, 1983

    Google Scholar 

  68. Samojlik E, Santen RJ, Worgul TJ: Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. Clin Endocrinol 20:43, 1984

    Google Scholar 

  69. Newsome HH, Brown PW, Terz JJ, Lawrence W Jr: Medical adrenalectomy and plasma steroids in advanced breast carcinoma. Surgery 83:83, 1978

    PubMed  Google Scholar 

  70. Buzdar AV, Powell KC, Legha SS, Blumenschein GR: Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer 50:1708, 1982

    PubMed  Google Scholar 

  71. Kaye SB, Woods RL, Fox RM, Coates AS, Tattersall MHN: Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Cancer Res 42 (Suppl): 3445S, 1982

  72. Paterson AG, Webster DJT: Adrenalectomy for advanced breast cancer: A reappraisal. Anticancer Res 3:151, 1983

    PubMed  Google Scholar 

  73. Tilson-Mallett N, Santner SJ, Feil PD, Santen RJ: Biological significance of aromatase activity in human breast tumours. J Clin Endocrinol Metab 57:1125, 1983

    PubMed  Google Scholar 

  74. Prost O, Turrel MO, Dahan N, Cravener C, Adessi GL: Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulphate levels in human breast carcinoma. Cancer Res 44:661, 1984

    PubMed  Google Scholar 

  75. Harris AL, Dowsett M, Smith IE, Jeffcoate SL: Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. Brit J Cancer 48:449, 1983

    Google Scholar 

  76. Dowsett M, Harris AL, Smith IE, Jeffcoate SL: Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. J Clin Endocrinol Metab 58:99, 1984

    PubMed  Google Scholar 

  77. Nickelsen T, Schulz F, Demisch K: Studies on cortisol substitution therapy in patients with adrenal insufficiency. Exp Clin Endocrinol 82:35, 1983

    PubMed  Google Scholar 

  78. Worgul TJ, Santen RJ: Recovery of the hypothalamicpituitary-adrenal axis after long term suppression by aminoglutethimide and hydrocortisone. 62nd Annu Meet Endocrine Soc, Washington: Abst 810, 1980

    Google Scholar 

  79. Cantwell BMJ, Sainsbury JRC, Harris AL, Wilson RG, Farndon J, Dawes PJDK, Dowsett M: Low dose aminoglutethimide. Phase II study in advanced postmenopausal breast cancer. Brit J Cancer 50:252, 1984

    Google Scholar 

  80. Bonterre J, Coppens H, Mauriac L, Mathieu M, Roverre J, Armand JP, Fargeot J, Metz M, Tubiana M, Cappelaere P: Aminoglutethimide 1 G v 500 mg in advanced breast cancer. III ECCO Conference, Abs 252, 1985

Download references

Author information

Authors and Affiliations

  1. Cancer Research Unit, University of Newcastle upon Tyne, Royal Victoria Infirmary, NE1 4LP, Newcastle upon Tyne, England

    A. L. Harris (Prof.)

Authors
  1. A. L. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harris, A.L. Could aminoglutethimide replace adrenalectomy?. Breast Cancer Res Tr 6, 201–211 (1985). https://doi.org/10.1007/BF01806770

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806770

Key words

Search

Navigation